摘要
目的评价早期应用18 F-脱氧葡萄糖(FDG)PET/CT显像预测新辅助化疗疗效的价值;比较最大标准摄取值(maximum standard uptake value,SUVmax)和靶组织/非靶组织(target organization/non-target organization,T/NT)评估新辅助化疗疗效方面的效能,选择评价疗效的合适指标及具体数值。方法前瞻性研究初治乳腺癌患者22例,在新辅助化疗前、第一疗程结束后及第二疗程结束后行18 F-FDG PET-CT显像并计算其SUVmax和T/NT的变化率。结果新辅助化疗有效组在第一疗程结束后SUVmax和T/NT比值下降率与无效组比较差异有统计学意义(P值均<0.05),根据受试者工作曲线(ROC曲线)分别得到第一疗程结束后的ΔSUVmax1%最佳预测疗效值为36.3%(敏感度为83.3%,特异性为80.0%),ΔT/N1%最佳预测疗效值为42.8%(敏感度为83.3%,特异性为86.7%);第二疗程结束后ΔSUVmax2%最佳预测疗效值为57.7%(敏感度为83.3%,特异性为93.3%),ΔT/N2%最佳预测疗效值为53.4%(敏感度为83.3%,特异性为73.3%)。结论第一疗程结束后18F-FDG PET-CT显像预测新辅助化疗疗效具有较好的可行性,支持有效者继续治疗;SUVmax在评价新辅助化疗疗效方面优于T/NT。
Objective To evaluate the value of early application 18F flurodeoxyglucose（FDG） PET/CT in breast cancer to neoadjuvant chemotherapy; and compare the efficiency on predicting the outcome of neoadjuvant chemotherapy between the changes of maximum standard uptake value（SUVmax） and target organization/non-target organization（T/NT）,so as to select suitable index and the specific values to evaluate the therapeutic effect. Methods In a prospective trial, 18 F-FDG PET-CT scans were performed in 22 women with primary breast cancer before neoadjuvant chemotherapy and after the first and second cycle of neoadjuvant chemotherapy,and the changes of SUVmax and T/NT were calculated. Results The responder group had a greater decline in SUV and T/NT than the non-responder group（P〈0.05）at the first cycle, under the ROC curves, the best prediction effect of ASUVmax % was 36. 3% （sensitivity 83.3 %, specificity 80.0% ）, the best prediction effect ofAT/NT1 % was 42.8 % （ sensitivity 83.3% , speci ficity 86. 7%）, the best prediction effect of ASUVmax2 % was 57. 7.3% （sensitivity 83.3%, specificity 93.3 % ）, the best prediction effect of AT/NT2 % was 53.4 % （sensitivity 83.3 %, specificity 73.3 % ）, respectively. Conclusion 18F-FDG PET-CT could be feasible to predict the pathological response of primary breast cancer after neoadjuvant chemotherapy at the first cycle,to support the effective patient to continue treatment,T/NT is no better than SUVmax on the neoajuvant chemotherapy efficacy evaluation in our research.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2012年第10期1224-1227,共4页
Cancer Research on Prevention and Treatment
